With offices in France (Paris) and in the USA (Princeton, New Jersey), STENTYS became listed on the Paris EuroNext stock exchange (STNT.PA) in October 2010. STENTYS® received CE-Marking for its BMS and DES(P) stents in early 2010 and currently sells its products in more than 8 European countries.
The STENTYS Clinical Program includes both randomised trials and real-life registries, evaluating the STENTYS stent in STEMI with the APPOSITION program, and in bifurcations with the OPEN program. STENTYS has started a 3,000 patient post-market registry in 2012 to examine the real-world use of the STENTYS stent where stent sizing is a concern.

Company Growth (employees)
Type
Public
HQ
Paris, FR
Founded
2006
Size (employees)
27 (est)
Stentys was founded in 2006 and is headquartered in Paris, FR

Stentys Office Locations

Stentys has offices in Paris and Princeton
Paris, FR (HQ)
18 Rue d'Hauteville
Princeton, US
103 Carnegie Center

Stentys Financials and Metrics

Stentys Financials

EUR

Market capitalization (31-Oct-2017)

32.4 m

Closing share price (31-Oct-2017)

1.8
Stentys's current market capitalization is €32.4 m.
Show all financial metrics

Stentys Market Value History

Stentys's Web-traffic and Trends

Stentys Online and Social Media Presence

Stentys Company Life and Culture

You may also be interested in